- Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel; Drug: Vaginal formulation (VF) of tenofovir 1% gel; Drug: Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel; Radiation: Radiolabeling of study drugs and semen
Sponsors: University of Pittsburgh; Ian McGowan; National Institute of Allergy and Infectious Diseases (NIAID); CONRAD
Not yet recruiting - verified April 2012 - Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel; Drug: Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel; Drug: Universal HEC Placebo Gel Formulation
Sponsors: University of Pittsburgh; Ian McGowan; National Institute of Allergy and Infectious Diseases (NIAID); CONRAD
Not yet recruiting - verified April 2012 - Conditions: Neuralgia; Postherpetic Neuralgia; Reflex Sympathetic Dystrophy
Interventions: Drug: Pennsaid topical 1.5% diclofenac; Drug: Placebo (2.3% DMSO solution)
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified March 2012 - Conditions: Heart Failure; Cardiomyopathy; Ventricular Dysfunction
Interventions: Biological: Mesenchymal Precursor Cell Injection; Biological: 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: Peanut Hypersensitivity; Food Hypersensitivity; Food Allergy; Peanut Allergy
Intervention: Drug: Liquid peanut extract
Sponsors: Duke University; Duke University; National Institute of Allergy and Infectious Diseases (NIAID); National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified June 2011
 |
Cryoprotective Clinical Trials |
